An earlier study shows that preeclampsia affects around seven percent of the pregnant women in the United States. Another study shows that preeclampsia may increase the risk of high blood sugar (glucose) levels (type 2 diabetes. T2D), high blood pressure (hypertension), heart diseases and stroke.
A study supported by the National Institutes of Health, Maryland, the United States at the Penn State shows a lifelong higher risk of cardiovascular diseases from pregnancy preeclampsia in women.
The researchers have observed a permanent dysfunction of blood vessels (change in the way the blood vessels function) in pregnant women who had pregnancy preeclampsia. Due to the permanent change in the functioning of the blood vessels, those women may face the lifelong higher risk of cardiovascular diseases, even though they might have recovered from the preeclampsia after giving birth. The researchers say that this study can help in developing better treatment options for the prevention of cardiovascular diseases.
Author of the study was Anna E. Stanhewicz, Department of Kinesiology, Pennsylvania State University. The study was published on September 12, 2017, in the Hypertension. Title of the article was "Increased Angiotensin II Sensitivity Contributes to Microvascular Dysfunction in Women Who Have Had Preeclampsia."
Postmenopausal women with breast cancer are being treated with an aromatase inhibitor (AIs). But the use of aromatase inhibitors (AIs) may increase the risk of cardiovascular diseases.
A study by the researchers from Princess Margaret Cancer Center, Toronto, Canada and the University of Toronto, Canada shows an increased risk of bone fractures and heart diseases such as heart attack, cardiovascular diseases, angina and heart failure with an extended or long-term use of aromatase inhibitors (AIs) in the early breast cancer treatment.
The current study was conducted on 16,349 patients. The study shows an increased unfavorable effect on cardiovascular health, bone fractures and discontinuation of the treatment with a long-term treatment of aromatase inhibitors (AIs). This study also shows an increased risk of cardiovascular diseases with the aromatase inhibitors (AIs) compared to tamoxifen in the treatment of breast cancer in women patients. The following table shows the risks with the use of aromatase inhibitors (AIs).
But researchers could not find out whether the risk reduction is due to the better protective effect of tamoxifen or the adverse risk is due to the aromatase inhibitors (AIs).
The author of the study was Dr. Eitan Amir, MB, ChB, Ph.D., senior fellow, Medical Oncologist, Princess Margaret Hospital, Toronto, Canada. The study was published on August 4, 2017, in the Journal of the National Cancer Institute. Title of the article was "Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis."
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. The published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.